These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9585800)

  • 1. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
    Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
    Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
    Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
    Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between ritonavir and clarithromycin.
    Ouellet D; Hsu A; Granneman GR; Carlson G; Cavanaugh J; Guenther H; Leonard JM
    Clin Pharmacol Ther; 1998 Oct; 64(4):355-62. PubMed ID: 9797791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
    van der Lugt J; Gorowara M; Avihingsanon A; Burger D; Ananworanich J; Sringam K; Kerr S; Wit F; Lange J; Ruxrungtham K
    AIDS; 2009 Jun; 23(9):1176-9. PubMed ID: 19451794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
    Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
    Kakuda TN; Falcon RW
    Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
    Winston A; Back D; Fletcher C; Robinson L; Unsworth J; Tolowinska I; Schutz M; Pozniak AL; Gazzard B; Boffito M
    AIDS; 2006 Jun; 20(10):1401-6. PubMed ID: 16791014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.
    Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW
    Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.
    la Porte CJ; Li Y; Béïque L; Foster BC; Chauhan B; Garber GE; Cameron DW; van Heeswijk RP
    Clin Pharmacol Ther; 2007 Oct; 82(4):389-95. PubMed ID: 17361121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
    Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
    J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
    Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
    Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
    Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
    Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
    Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
    Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.
    Sekar VJ; Lefebvre E; Mariën K; De Pauw M; Vangeneugden T; Hoetelmans RM
    Ther Drug Monit; 2007 Dec; 29(6):795-801. PubMed ID: 18043478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.
    Lledó-García R; Nácher A; Casabó VG; Merino-Sanjuán M
    Drug Metab Dispos; 2011 Feb; 39(2):294-301. PubMed ID: 20978105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.
    Khaliq Y; Gallicano K; Venance S; Kravcik S; Cameron DW
    Clin Pharmacol Ther; 2000 Dec; 68(6):637-46. PubMed ID: 11180024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.